NCT02294630View on ClinicalTrials.gov

Aerosolized Surfactant in Neonatal RDS

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2020

Conditions
Respiratory Distress Syndrome, Newborn
Interventions
DRUG

Surfactant

Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.

Trial Locations (1)

48201

Hutzel Women's Hospital, Detroit

All Listed Sponsors
lead

Sood, Beena G., MD, MS

INDIV

NCT02294630 - Aerosolized Surfactant in Neonatal RDS | Biotech Hunter | Biotech Hunter